Allergan Inc. (AGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Allergan fell $1.08 (-1.2%) to $90.89 on light volume. Throughout the day, 1,696,731 shares of Allergan exchanged hands as compared to its average daily volume of 3,051,000 shares. The stock ranged in price between $90.49-$92.29 after having opened the day at $91.88 as compared to the previous trading day's close of $91.97. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 34.6%, Oxygen Biotherapeutics ( OXBT), down 23.9%, CEL-SCI Corporation ( CVM), down 17.1% and Senesco Technologies ( SNTI), down 12.7%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.2 billion and is part of the health care sector. Shares are up 0.3% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Biocryst Pharmaceuticals ( BCRX), up 51.2%, TrovaGene ( TROV), up 21.3%, Chelsea Therapeutics International ( CHTP), up 16.0% and PetMed Express ( PETS), up 13.6% , were all gainers within the drugs industry with Teva Pharmaceutical Industries ( TEVA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.